US 11,053,214 B2
Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Brigida Allieri, Verona (IT); Paul Fagan, Cambridge, MA (US); Emma Sharp, London (GB); and Raymond D. Skwierczynski, Cambridge, MA (US)
Assigned to CoLucid Pharmaceuticals, Inc., Indianapolis, IN (US)
Appl. No. 16/467,208
Filed by COLUCID PHARMACEUTICALS, INC., Indianapolis, IN (US)
PCT Filed Dec. 5, 2017, PCT No. PCT/US2017/064652
§ 371(c)(1), (2) Date Jun. 6, 2019,
PCT Pub. No. WO2018/106657, PCT Pub. Date Jun. 14, 2018.
Claims priority of provisional application 62/430,662, filed on Dec. 6, 2016.
Prior Publication US 2020/0087279 A1, Mar. 19, 2020
Int. Cl. C07D 401/06 (2006.01)
CPC C07D 401/06 (2013.01) [C07B 2200/13 (2013.01)] 7 Claims
 
1. A crystalline Form D di-hydrate of the hemisuccinate salt of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide characterized by an X-ray diffraction pattern when measured using Cu-Kα radiation having at least peaks at about 18.7+/−0.2 degrees 2θ, 26.5+/−0.2 degrees 2θ, 27.0+/−0.2 degrees 2θ, 27.5+/−0.2 degrees 2θ and 27.8+/−0.2 degrees 2θ.